Literature DB >> 7979222

Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.

F J Vingerhoets1, B J Snow, C S Lee, M Schulzer, E Mak, D B Calne.   

Abstract

Previous estimates of the rate of progression of the nigral pathology underlying idiopathic parkinsonism (IP) have been derived mainly from pathological studies that have an inherent selection bias. Fluorodopa positron emission tomography (PET) is a reliable tool for assessing nigrostriatal dopaminergic function in vivo. We performed fluorodopa PET on two occasions, 7 years apart, on 16 patients with IP (age at the time of the first scan, 51 +/- 14 yr [mean +/- SD]) and 10 normal controls (age, 54 +/- 16 yr). For the patients with IP, the average duration of symptoms from the time of diagnosis to the first scan was 4.5 years (range, 1-12 yr); their PET index (striatal-occipital)/occipital ratio, dropped by 1.7% per year, from 0.49 +/- 0.08 to 0.43 +/- 0.08 (p < 0.001). The normals' ratio decreased by 0.3% per year from 0.77 +/- 0.05 to 0.75 +/- 0.10 (p = 0.33). The ratios in the IP group progressed significantly faster than the controls (p = 0.036). The rate of decline in IP represents 7.8% per decade, expressed as a fraction of the normals' initial mean value at 54 years of age. These results also permit power analysis for the design of future studies assessing the effect of treatment on the underlying pathology in IP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979222     DOI: 10.1002/ana.410360512

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

1.  Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease.

Authors:  K Dujardin; A Duhamel; E Becquet; C Grunberg; L Defebvre; A Destee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.

Authors:  A Winogrodzka; P Bergmans; J Booij; E A van Royen; J C Stoof; E C Wolters
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

3.  Premotor Parkinson's disease: concepts and definitions.

Authors:  Andrew Siderowf; Anthony E Lang
Journal:  Mov Disord       Date:  2012-04-15       Impact factor: 10.338

Review 4.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

Review 5.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

Review 6.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

7.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

8.  Transcranial sonography of the substantia nigra: digital image analysis.

Authors:  D Skoloudík; M Jelínková; J Blahuta; P Cermák; T Soukup; P Bártová; K Langová; R Herzig
Journal:  AJNR Am J Neuroradiol       Date:  2014-07-24       Impact factor: 3.825

9.  In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers.

Authors:  Andre C Felicio; Katherine Dinelle; Pankaj A Agarwal; Jessamyn McKenzie; Nicole Heffernan; Jeremy D Road; Silke Appel-Cresswell; Zbigniew K Wszolek; Matthew J Farrer; Michael Schulzer; Vesna Sossi; A Jon Stoessl
Journal:  Mov Disord       Date:  2014-05-05       Impact factor: 10.338

10.  Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation.

Authors:  R Hilker; A T Portman; J Voges; M J Staal; L Burghaus; T van Laar; A Koulousakis; R P Maguire; J Pruim; B M de Jong; K Herholz; V Sturm; W-D Heiss; K L Leenders
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.